Sage Therapeutics (SAGE)
(Delayed Data from NSDQ)
$11.70 USD
-0.31 (-2.58%)
Updated May 17, 2024 04:00 PM ET
After-Market: $11.70 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth D Momentum F VGM
Brokerage Reports
Sage Therapeutics, Inc. [SAGE]
Reports for Purchase
Showing records 21 - 40 ( 158 total )
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Zurzuvae Pricing Announced, Rollout Begins In December
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Provider: Zacks Investment Research
Analyst: Research Department
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Anticipated Restructuring Arrives, As SAGE Prepares For Zurzuvae Launch
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
The Future for Zuranolone in MDD Seems Uncertain; Adjusting PT to $27; Reit. Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Approval in Postpartum Depression Still Leaves Sage Short After CRL in MDD; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Biotechnology- Moving To Neutral On SAGE; Drug Approvals Don''''t Normally Give You The Blues
Provider: Wedbush Securities Inc.
Analyst: CHICO L
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Takeaways From Our Conversation with Sage Therapeutics Management
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Takeaways from Company Presentations at Tremor Congress 2023
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Pre-Launch Activities Escalate Ahead of August 5 PDUFA for Zuranolone; Maintain Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
Company: Sage Therapeutics, Inc.
Industry: Medical - Drugs
FDA accepts NDA for Zuranolone but More Data Might be Needed; Reiterate Neutral
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D